AARD NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Aardvark Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 6.60 USD
4.4% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 22.3% of its 52-week range. The latest completed week returned 4.4%, after a 15.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 27/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 9d.

Setup score 35 out of 100
Latest Close 6.60 USD 31 Jul 2026
1W Return 4.4% latest completed week
4W Return 15.8% short-term follow-through
12W Return 21.3% quarterly tape
Trend Breadth 30.8% 16 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.4% Latest completed week; four-week move 15.8%. Indicator stack 17/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 27/100 conviction; expected move 84.1%. News sentiment 48/100 63 relevant articles in the latest sentiment read. Event risk 9d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 22.3% of its 52-week range. The latest completed week returned 4.4%, after a 15.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1312-week average 0.13

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.13Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 15.8% over four weeks, 21.3% over 12 weeks, and -45.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.4%
4W15.8%
12W21.3%
26W-49.2%
52W-45.6%
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.72Latest activity-pressure read.
Pressure change123.1%Four-week change in activity pressure.
Leadership-34.92Latest relative-leadership reading.
RS change29.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 63%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength76/100Blend of value, momentum, and quality. Underlying universe rank 25; rank 1 is best.
Value63/100Relative valuation strength. Underlying universe rank 38; rank 1 is best.
Quality61/100Profitability and accounting quality. Underlying universe rank 40; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-74.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-210.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

AARD shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 84.1%, and Sharemaestro trend signal inactive.

Conviction27/100
Expected move84.1%
Put/call volume
Pressure9
Speculation0
Volatility96
Trend agreement53
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 63 relevant articles.

12 positive · 40 neutral · 11 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings9dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move84.1%Nearest-chain priced movement where available.
52-week drawdown-63.2%Distance below the 52-week high.
13-week volatility15.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+33.3%Week of 10 Jul.
Worst week-53.2%Week of 6 Mar.
Latest week+4.4%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses3
Sharp losses10
Recent vol15.1%13-week weekly-return volatility.
Base vol15.7%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew12.8% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis21/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.13; No reversal markers Factors65/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 46; Small Cap Core rank 46 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

AARD shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 84.1%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 84.1% Sentiment48/100

Weighted news tone is neutral across 63 relevant articles.

Aardvark shares plunge 32% after FDA halts clinical trial for Prader-Willi Syndrome drug. Insiders50/100

No recent insider transaction evidence is stored.

 Earnings9d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.60 USD4.4%7.24 USD9.71 USD0.72-34.92539.6KOff
24 Jul 20266.32 USD7.8%7.46 USD9.75 USD0.71-38.33848.7KOff
17 Jul 20265.86 USD-22.9%7.70 USD9.79 USD0.72-44.921.6MOff
10 Jul 20267.60 USD33.3%7.96 USD9.85 USD0.56-32.595.2MOff
3 Jul 20265.70 USD19.0%8.19 USD9.88 USD0.32-49.25851.0KOff
26 Jun 20264.79 USD21.9%8.45 USD9.93 USD0.07-57.872.4MOff
19 Jun 20263.93 USD0.8%8.63 USD10.01 USD-0.23-67.67554.1KOff
12 Jun 20263.90 USD6.0%8.81 USD10.09 USD-0.39-67.66546.3KOff
5 Jun 20263.68 USD-10.5%9.01 USD10.18 USD-0.54-69.31709.5KOff
29 May 20264.11 USD-9.5%9.22 USD10.28 USD-0.63-67.89716.7KOff
22 May 20264.54 USD-0.7%9.44 USD10.37 USD-0.74-64.09892.6KOff
15 May 20264.57 USD-16.0%9.65 USD10.46 USD-0.84-63.981.4MOff
8 May 20265.44 USD-0.4%9.92 USD10.55 USD-0.93-57.83547.7KOff
1 May 20265.46 USD1.3%10.29 USD10.63 USD-1.00-55.99532.7KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.